Myesha Lacy
Investor Relations Kontakt bei ARCELLX, INC.
Aktive Positionen von Myesha Lacy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ARCELLX, INC. | Investor Relations Kontakt | 01.06.2021 | - |
Karriereverlauf von Myesha Lacy
Ehemalige bekannte Positionen von Myesha Lacy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Investor Relations Kontakt | - | - |
| Public Communications Contact | - | - | |
| ZS PHARMA INC | Investor Relations Kontakt | - | - |
| Public Communications Contact | - | - | |
| HYPERION THERAPEUTICS INC | Investor Relations Kontakt | - | - |
| Public Communications Contact | - | - | |
| GLOBAL BLOOD THERAPEUTICS, INC. | Investor Relations Kontakt | 01.04.2016 | - |
| Public Communications Contact | 01.04.2016 | - |
Ausbildung von Myesha Lacy
| Holy Names University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Investor Relations Contact | 5 |
| Public Communications Contact | 4 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ARCELLX, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
- Börse
- Insiders
- Myesha Lacy
- Erfahrung
